
    
      It's a prospective, non-interventional, observational Post-marketing Surveillance, the aim of
      the surveillance is to observe the safety and overall effectiveness of Latuda® in the
      treatment of Chinese patients with schizophrenia for 12 weeks in real clinical practice, as
      well as the dose of Latuda® for monotherapy or combination therapy.
    
  